New York Clinical Trials Report — April 2026

For New Yorkers considering participation in clinical research, April 2026 presents a critical window to act, especially for those interested in trials nearing their enrollment deadlines. Across the state, a substantial number of studies are closing soon, with 340 trials slated to conclude within the next 90 days. This includes a significant opportunity for healthy volunteers, as 65 of these rapidly closing studies are still actively seeking participants without specific health conditions. If you've been contemplating joining a trial, now is the time to explore these options before they are no longer available.

Patients managing certain health challenges also face impending deadlines to join research. Trials focused on various types of cancer and neurological conditions are among those with limited time remaining for enrollment. Conditions with trials closing soon include:

• Breast cancer (12 trials)
• Cancer (5 trials)
• Glioblastoma (4 trials)
• Major depressive disorder (4 trials)
• Ovarian cancer (4 trials)
• Prostate cancer (4 trials)
• Pancreatic cancer (4 trials)
• Alzheimer disease (4 trials)
• Mild cognitive impairment (3 trials)
• Lung cancer (3 trials)

Major Advancements and New Research Horizons

This month brings several high-profile new trials to New York, including significant Phase 3 studies from major pharmaceutical companies and leading academic institutions. These trials offer participants the chance to engage with cutting-edge treatments and diagnostic tools, addressing a range of health challenges from metabolic disorders to advanced cancers and rare diseases.

• Novo Nordisk A/S is sponsoring two notable Phase 3 studies investigating the medicine NNC0487-0111. NCT07533175, "AMAZE 2," is designed for 630 participants with excess body weight and Type 2 diabetes, aiming to assess the safety and effectiveness of this weekly injectable treatment. Another trial, NCT07509307, "AMAZE 6," focuses on 400 participants with excess body weight and knee osteoarthritis, evaluating the same medicine's effect on weight loss and pain reduction.
• Incyte Corporation is launching NCT07522073, a Phase 3 study for 588 participants with previously untreated, KRAS G12D-Mutated metastatic pancreatic ductal adenocarcinoma. This important oncology trial evaluates chemotherapy with or without INCB161734.
• Memorial Sloan Kettering Cancer Center is leading NCT07507643, a Phase 3 study involving 750 participants to test whether methylprednisolone administered before liver surgery can reduce side effects like infections and shorten hospital stays.
• The University of Rochester is sponsoring NCT07505342, an observational study for 1,000 participants with Myotonic Dystrophy. This unique trial uses remote assessments from participants' homes, requiring no travel to a study site, to better understand disease variability.
• Columbia University is initiating NCT07511621, a project for 500 participants focused on a multi-level strategy to reduce the overuse of screening mammography in women aged 75 years and older.
• The VA Office of Research and Development is conducting NCT07507747, an adaptive intervention study for 384 primary care Veterans with psychological distress, testing peer-supported mobile health solutions.
• Caliway Biopharmaceuticals Co., Ltd. is sponsoring NCT07526974, a Phase 3 study for 320 participants to evaluate the efficacy and safety of CBL-514 injection for reducing abdominal subcutaneous fat.

April's Research Landscape: New Opportunities and Geographic Reach

This month, New York saw the opening of 39 new clinical trials, a decrease from the 70 trials that launched in March 2026. Despite this dip, the state continues to offer a diverse array of research opportunities, with a total of 4,396 clinical trials currently recruiting across 201 cities and 2,974 research sites.

The majority of new research initiatives this month are concentrated in New York City and its surrounding areas. New York City itself saw 25 new trials open, reflecting its status as a major research hub. Other cities with new trial openings include:

• Commack (5 trials)
• Harrison (5 trials)
• The Bronx (4 trials)
• Brooklyn (2 trials)
• Rochester (2 trials)
• Rockville Centre (2 trials)
• Syracuse (2 trials)
• Uniondale (2 trials)
• Dryden (1 trial)

While a significant portion of new trials are in metropolitan centers, the overall research landscape remains broadly accessible across New York, with studies spanning a wide geographic distribution.

New studies are exploring a range of conditions, from common ailments to more specialized areas. This month's new trials are targeting conditions such as:

• Overweight (2 trials)
• Obesity (2 trials)
• Non-small cell lung cancer (2 trials)
• Advanced melanoma (1 trial)
• Artificial intelligence (AI) (1 trial)
• Brain tumors (1 trial)
• Arthritis (1 trial)
• Cancer related fatigue (1 trial)
• Central centrifugal cicatricial alopecia (1 trial)
• Coronary artery disease (CAD) (1 trial)

Among the 39 new trials, drug studies were the most prevalent, with 20 new drug trials opening. Device trials followed with 8, and behavioral studies with 7, showcasing a diverse approach to medical innovation.

Participation Opportunities: Healthy Volunteers and Specific Demographics

Participation in clinical trials is open to a wide range of individuals. Of the 39 new trials launched this month, 33 include older adults, ensuring that senior populations have ample opportunity to contribute to medical science. Additionally, 5 new trials are specifically designed for female participants.

For individuals without a specific medical condition, there are significant opportunities to contribute. 11 of the new trials this month are actively seeking healthy volunteers. Across New York, a total of 578 clinical trials are currently recruiting healthy participants, providing numerous avenues for those interested in supporting medical research.

Academic institutions continue to play a vital role in New York's research ecosystem, with Memorial Sloan Kettering Cancer Center sponsoring 5 of the new trials, NYU Langone Health sponsoring 4, and the University of Rochester, Icahn School of Medicine at Mount Sinai, and Weill Medical College of Cornell University each sponsoring 2. Industry sponsors, including Novo Nordisk A/S (2 trials) and Eli Lilly and Company (1 trial), are also driving significant research efforts.

As we move through spring, the focus will likely shift towards the ongoing enrollment in these significant Phase 3 trials, while researchers prepare for the next wave of innovative studies to address a broad spectrum of health challenges across New York.